A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects

Journal of Infectious Diseases

Volumn 183, Issue 8, 2001, Pages 1171-1179

  Berencsi, Klara ^a   Gyulai, Zsofia ^a   Gonczol E ^a   Pincus, Steve ^d,g   Cox, William I ^d   Michelson, Susan ^e   Kari, Laszlo ^a   Meric, Claude ^g   Cadoz, Michel ^g   Zahradnik, John ^c   Starr, Stuart ^b   Plotkin, Stanley ^c  

^a WISTAR INSTITUTE   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c SANOFI PASTEUR   (France)

^d Virogenetics Inc   (United States)

^e INSTITUT PASTEUR   (France)

^f EluSys Therapeutics   (United States)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; PLACEBO; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VCP 260; VIRUS PHOSPHOPROTEIN; VIRUS VECTOR;

ADULT; ARTICLE; CELL PROLIFERATION; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTACT DERMATITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; FEMALE; HEADACHE; HELPER CELL; HUMAN; HUMAN EXPERIMENT; IMMUNIZATION; LYMPHOCYTE PROLIFERATION; MALAISE; MALE; MONONUCLEAR CELL; MYALGIA; NAUSEA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RASH; T LYMPHOCYTE SUBPOPULATION;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; AVIPOXVIRUS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOTOXICITY, IMMUNOLOGIC; GENETIC VECTORS; HUMANS; IMMUNITY, CELLULAR; PHOSPHOPROTEINS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER; VACCINES, SYNTHETIC; VIRAL MATRIX PROTEINS; VIRAL VACCINES;

EID: 0035871756     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/319680     Document Type: Article

References (52)

1. Congenital cytomegalovirus infection: The relative importance of primary and recurrent maternal infection
2. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status
3. Symptomatic congenital cytomegalovirus infection in infants born to mothers with preexisting immunity to cytomegalovirus
4. Cytomegalovirus
5. Effect of OKT3 antibody therapy on cytomegalovirus reactivation in renal transplant recipients
6. Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: Transmission by donated organ and the effects of OKT3 antibodies
7. Cytotoxic T cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients
8. Cytotoxic T lymphocyte response to cytomegalovirus following human allogeneic bone marrow transplantation: Pattern of recovery and correlation with cytomegalovirus infection and disease
9. Cytomegalovirus-specific T-cell immunity in recipients of autologous peripheral blood stem cell or bone marrow transplants
10. Cytomegalovirus (CMV)-specific T cell immunity after renal transplantation mediates protection from CMV disease by limiting the systemic virus load
11. + cytotoxic T lymphocyte responses to human cytomegalovirus in immunodeficient humans by the adoptive transfer of T cell clones
12. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant correlation with CMV disease and effect of ganciclovir prophylaxis
13. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor
14. Human cytomegalovirus-specific cytotoxic T cells
15. Fine specificity of cellular immune responses in humans to human cytomegalovirus immediate-early 1 protein
16. Selective interference with class I major histocompatibility complex presentation of the major immediate-early protein following infection with human cytomegalovirus
17. Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous vital gene expression
18. + virus-specific cytotoxic T lymphocytes
19. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: Frequency, specificity, and T-cell receptor usage of pp65-specific CTL
20. Cytotoxic T cell immunity to human cytomegalovirus glycoprotein B
21. Recognition ofhuman cytomegalovirus gene products by HCMV-specific cytotoxic T cells
22. +-T-cell response to human cytomegalovirus: The 72-kilodalton major immediate-early protein revisited
23. Cytotoxic T lymphocyte (CTL) responses to HCMV pp65, IE1 exon 4, gB, pp150, and pp28 in healthy seropositive individuals: Reevaluation of prevalence of IE-specific CTL
24. Potential use of nonreplicating vectors as recombinant vaccines
25. NYVAC: A highly attenuated strain of vaccinia virus
26. The safety and use of canarypox vectored vaccines
27. Immunization with canarypox virus expressing rabies glycoprotein
28. Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: An alternative poxvirus vector system
29. Nonreplicating vital vectors as potential vaccines: Recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins
30. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI)
31. SF2 recombinant gp 120, or both vaccines in seronegative adults
32. + cytotoxic T lymphocyte responses in seronegative volunteers
33. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne) in humans
34. A rapid microneutralization assay for cytomegalovirus
35. Structural analysis of a 64-kDa major structural protein of human cytomegalovirus (Towne) identification of a phosphorylation site and comparison to pp65 of HCMV (AD169)
36. Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB)-specific neutralizing antibody and phosphoprotein 65 (pp65)-specific cytotoxic T lymphocyte responses by naked DNA immunization
37. Safety immunogenicity of the Towne strain cytomegalovirus vaccine
38. Development of a candidate HLA 0201-restricted peptide-based vaccine against human cytomegalovirus infection
39. Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides
40. Comparison restriction site polymorphisms among clinical isolates and laboratory strains of human cytomegalovirus
41. Human cytomegalovirus DNA: BamHI, EcoRI, and PstI restriction endonuclease cleavage maps
42. Cleavage maps for human cytomegalovirus DNA strain AD169 for restriction endonucleases EcoRI, BgIII, and HindIII
43. Human cytomegalovirus DNA: Physical maps for restriction endonucleases BgIII, HindIII, and XbaI
44. Comparison of the physical maps of the DNAs of two cytomegalovirus strains
45. Frequency distribution of cytomegalovirus envelope glycoprotein genotypes in bone marrow transplant recipients
46. Cytomegalovirus glycoprotein B groups associated with retinitis in AIDS
47. Human cytomegalovirus glycoprotein B genotypes in renal transplant recipients
48. Cytomegalovirus gB genotype distribution differs in human immunodeficiency virus-infected patients and immunocompromised allograft recipients
49. Glycoprotein B subtyping of cytomegalovirus (CMV) in the vitreous of patients with AIDS and CMV retinitis
50. Influence of strong CD4 epitope on long-term virus-specific cytotoxic T cell responses induced in vivo with peptides
51. + cells but markedly decreased helper cell activity in mice lacking CD4